Back to catalogue
№ 306 22 filings · 2021-10-29 → 2026-09-25

NARF INDUSTRIES PLC

NARF
Technology Share price 0.33p Market cap £5.52m Overall fit 175 /1000

Genuine but sub-scale AI-cyber angle with strong operating leverage on paper, but the fragile balance sheet, going-concern warning, DARPA concentration and near-certain dilution make it a poor fit for a valuation-disciplined AI-receiver strategy that requires acceptable downside protection.

Fair value range 0p–1p Mid case · £5.95m
Absolute upside +7.9% vs current market cap
Conviction 2/5 confidence in fair call
Supports the call
  • clean FY26 audit with detailed segment/customer disclosure
  • tiny 15-person cost base makes operating leverage math tractable
  • CEO loan and shareholding align management with equity
Limits the call
  • going-concern material uncertainty flagged by auditor
  • valuation is dominated by UPxi commercialisation optionality
Methodology

1.0x-2.0x forward revenue on backlog plus UPxi option credit

In one line · bull case

A tiny, cost-disciplined DARPA-funded cyber R&D group whose commercial UPxi agentic-AI platform could inflect the P&L, if it survives to commercialise it.

In one line · biggest risk

Loss of a further DARPA contract while net liabilities stand at $3.5m and cash at $77k forces an equity raise at a price that permanently dilutes any AI-optionality value.

Drivers
AI beneficiary 45 /100
Agentic-AI software-supply-chain platform UPxi exists and is Platform One 'Awardable', but AI-driven revenue is <5% of the business today.
Operating leverage 70 /100
15-person cost base, ~$2m fixed opex; FY26 revenue up 50% with opex flat — incremental $ drops through at ~36% gross margin.
Earnings vs expectations 35 /100
Repeated misses vs prior aspirational guidance (2023 $5.8m target, FY25 revenue collapse in H1), plus July 2026 contract cancellation announced with FY26 results.
Growth momentum 60 /100
Revenue +50% in FY26 to $4.5m and $4.1m FY27 backlog; offset by July 2026 contract cancellation and low absolute scale.
Moat 35 /100
Specialised DARPA relationships and Platform One awardable status provide some barrier, but the group is a supplier not a platform and is easily displaced.
Earnings quality 30 /100
FY22 audit was disclaimed; FY25 qualified on opening balances; material related-party transactions (CEO loan, related-party office lease, CEO-owned customer).
Management quality 40 /100
CEO owns ~30% and funds the company personally, but historical governance/audit failures and repeated missed guidance limit the score.
Cyclicality 30 /100
US government R&D contracts show low economic cyclicality but are exposed to federal budget/shutdown risk rather than the business cycle.
Leverage 70 /100
Technically negative equity, no external debt but $3.3m CEO loan repayable on demand under certain conditions — high effective leverage.
Value-trap signals · 6
  • Auditor going-concern material uncertainty
  • Prior year audit disclaimer of opinion (FY22)
  • Repeated pre-emption waivers and dilution overhang (274m options + 41m warrants)
  • Extreme customer concentration (DARPA 83.6% of FY26 revenue)
  • Related-party CEO loan of $3.3m and CEO-owned counterparty transactions
  • Recent contract cancellation announced 20 July 2026

NARF Industries PLC (LSE: NARF) — Investment Research Note

Executive summary

NARF Industries is a sub-scale US cybersecurity R&D group whose revenue is dominated (83.6% in FY26) by a single US government customer, DARPA, while it attempts to commercialise its government-funded IP into a nascent agentic-AI software-supply-chain platform (UPxi, formerly Ranger/SocialCyber). FY26 delivered 50% revenue growth to $4.5m with essentially flat opex ($2.0m), narrowing the operating loss to $0.8m, but the group still carries net liabilities of $3.5m, only $77k of cash, and funds itself via a $3m related-party loan from the CEO extended to July 2027 2026-07 Final Results. The single most important valuation point today is that the equity is a levered call option on UPxi commercialisation — the going-concern basis is explicitly caveated with "material uncertainty" 2026-07 Final Results, Note 2.4.

Fair value estimate

  • Fair value range: 0.20p – 0.50p per share (implied mcap £3.4m – £8.5m)
  • Methodology: hybrid revenue-multiple / probability-weighted commercialisation option. There is no PBT, no book value support (negative equity of $3.5m), and no dividend. I anchor on: (i) FY27 contracted backlog of ~$4.1m (management guides "strong growth year") 2026-07 Final Results; (ii) a 1.0x–2.0x forward revenue multiple appropriate for sub-scale, single-customer-concentration government services (peers such as Kromek, Corero trade in a similar band despite being larger); (iii) an ~£1–2m implicit optionality credit for UPxi if the SI-led partner-channel gains a second customer.
    • Bear (0.20p): FY27 revenue delivers backlog only (~$4.1m), no UPxi commercial revenue, 1.0x sales, discount for going-concern overhang and probable equity issuance to clear the CEO loan → ~£3.5m mcap.
    • Base (0.35p): FY27 ~$5–6m revenue, modest UPxi optionality, 1.5x sales → ~£6m mcap.
    • Bull (0.50p): $6m+ revenue, UPxi lands second and third phases, 2x sales + option value → ~£8.5m mcap.
  • Comparison to current mcap of £6.8m at 0.40p: the market is already pricing in a fair-to-optimistic case. Absolute upside/downside to the mid (0.35p): –12.5%. The stock looks approximately fair-valued, with asymmetric downside if the DARPA contract that was cancelled in July 2026 is a leading indicator 2026-07 Final Results, Executive Chair's Statement.

Sector context

Confirmed sector: Technology / Cybersecurity Services (government). On quality, growth and leverage this company is materially below typical LSE cybersecurity peers: it is 1/10th the scale of Kape Technologies (delisted), a fraction of Corero Network Security or Kromek, and lacks the recurring SaaS revenue mix seen at Darktrace or CrowdStrike. Closest listed comparators: Corero Network Security (CNS.L), Kromek (KMK.L), Osirium Technologies (OSI.L) — all also sub-scale UK cyber-adjacent names with going-concern/dilution histories.

Investment thesis (3 bullets)

  • Operating leverage in a genuinely fixed-cost model. FY26 revenue grew 50% while direct salaries actually fell and total opex was ~flat, so gross profit swung from $415k to $1.6m and the operating loss shrank ~76% 2026-07 Final Results, Note 3. If FY27 delivers the $4.1m backlog plus proposal wins, incremental revenue drops to profit at gross-margin economics (~36%) with little added overhead.
  • Genuine AI-receiver angle at the UPxi layer. The Ranger→UPxi platform is positioned as agentic AI for open-source software supply-chain security, has "Awardable" status on the DoD Platform One marketplace, and secured a low-six-figure first commercial contract via a systems-integrator partner 2026-04 Trading Update; 2025-11 Interim Results. If UPxi lands its next 2–3 government agencies on P1, this can inflect from R&D shop to product company.
  • Skin in the game and cost discipline. CEO Steve Bassi owns ~30% and funds working capital via a $3m loan extended to July 2027 while waiving his own salary 2026-07 Final Results, Notes 13, 20. Combined with a fully diluted, tiny 15-person team, this creates the alignment and cost flexibility to survive to inflection.

Key risks (3 bullets)

  • Single-customer concentration and one recent cancellation. DARPA was 83.6% of FY26 revenue, and management disclosed on 20 July 2026 that "further work on one GR&D contract had been cancelled following the customer's decision to pursue an alternative technical approach" 2026-07 Final Results. A second such event would blow through the $4.1m backlog assumption.
  • Balance sheet is negative equity with a going-concern caveat. Net liabilities of $3.5m, only $77k of cash, and total liabilities of $4.4m against $0.9m of assets 2026-07 Final Results, SoFP. Auditors flagged "material uncertainty…may cast significant doubt on the Group's ability to remain a going concern" [Note 2.4]. Prior audits (FY22) received a disclaimer of opinion 2023-07 Final Results. An eventual equity raise or debt-for-equity of the CEO loan is highly likely.
  • Dilution overhang from 274m options + 41m warrants + potential fundraise. 316m instruments outstanding (18.6% of current share count) at 1p strike vs. 0.4p share price — dilutive if the shares recover 2026-07 Final Results, Note 15. Any placing to clear the $3.3m CEO loan at current prices would issue >600m new shares (~+36%).

Operating leverage

This is the single most attractive feature of the business. Fixed-cost share is very high: direct salaries plus operating expenses were $4.0m in FY26 on 15 employees whose cost base barely flexes with revenue. Gross margin was 35.7% (FY25: 13.8%) and would rise further as pass-through sub-contract costs compress. Modelling a 15% revenue upside to $5.2m in FY27 at unchanged opex: gross profit would rise ~$260k while opex stays flat, taking operating loss to roughly –$550k or break-even at $6m. A 20% revenue beat vs. the $4.1m contracted backlog alone would essentially wipe out the operating loss; at $6–7m revenue the group turns profitable, and every dollar above that drops through at ~36% gross margin against a static cost base. There is a clear inflection point at ~$6m revenue and further leverage if UPxi SaaS revenues (higher gross margin) become material. Cited: [2026-07 Final Results, Notes 3 & 4].

Value-trap signals

  • Repeated dilution and pre-emption waivers passed at AGMs (both 2025 and 2026) 2026-09 Result of AGM — the pattern of a chronically cash-thin sub-scale listing.
  • History of audit disclaimers — FY22 accounts received a disclaimer of opinion; FY25 audit report qualified over opening balances 2023-07 Final Results; 2025-11 Interim Results.
  • Related-party dependence — CEO loan of $3.3m, related-party office lease with entity owned by the CEO, revenue of $90k from Swarm Technologies (CEO-owned) 2026-07 Final Results, Note 20. Not fatal, but material.
  • Recent contract cancellation just before final results — the kind of drip of bad news typical of value traps 2026-07 Final Results.
  • Going-concern warning present in the audit report itself — a red flag on its own.

Earnings vs. expectations

The filings provide only management-guided targets rather than external analyst consensus (broker is Tennyson Securities; no visible consensus in public filings). Track record:

  • FY23 (year to 31-Dec-22): delivered $2.5m revenue and $2.6m operating loss versus prior "$5.8m 2023 revenue" management guidance — the audit was delayed, shares were suspended, opinion disclaimed 2023-07 Final Results. Missed.
  • FY25 (year to Mar-25): $3.0m revenue delivered after H1-25 revenue collapsed to $1.18m due to "temporary US government budget delays"; management had earlier warned via 7 Nov 2024 RNS. Missed prior expectations.
  • FY26 (year to Mar-26): Delivered $4.5m vs 16-Apr trading update of "$4.2m" and vs FY27 guidance of "$5.3m contracted backlog" (later trimmed to $4.1m in final results) 2026-04 Trading Update; 2026-07 Final Results. Mixed – revenue slight beat, backlog trimmed.

Pattern: management has repeatedly set ambitious targets and either delivered late or below. FY26 was the first cleaner year. The July 2026 contract cancellation adds fresh risk to FY27.

Conviction

Conviction: 2 (low).

Anchors: (i) clean, timely FY26 audit with fully audited comparatives now available; (ii) the operating-leverage math is easy to model with only 15 employees; (iii) the customer list is disclosed at the individual level.

Caveats: (i) fair value depends heavily on whether UPxi commercialises — a genuinely optionality-driven story where any number in the range is defensible; (ii) auditor going-concern warning and $3m related-party funding structure mean the equity is one bad contract cancellation away from being unrecognisable after a rescue raise; (iii) at £6.8m mcap and 0.40p share price with 1.7bn shares outstanding, tiny liquidity means realised price can decouple from any fundamental fair-value estimate.

Filings consulted · 25

Every document the LLM read for this note. Click any row to open the source.

  1. 2026-09-25Result OF Agm2026-09-25_9790277_result-of-agm.md0.30
  2. 2026-07-31Final Results2026-07-31_9697059_final-results.md1.00
  3. 2026-04-16Trading Update And New Contract Win2026-04-16_9522675_trading-update-and-new-contract-win.md0.85
  4. 2026-03-26Investor Presentation2026-03-26_9492591_investor-presentation.md0.59
  5. 2025-11-17Interim Results Amp Notice OF Investor Presentation2025-11-17_9236516_interim-results-amp-notice-of-investor-presentation.md0.77
  6. 2025-10-02Result OF Agm2025-10-02_9147019_result-of-agm.md0.26
  7. 2025-09-04Notice OF Agm2025-09-04_9087992_notice-of-agm.md0.20
  8. 2025-07-24Investor Presentation2025-07-24_8996339_investor-presentation.md0.46
  9. 2024-12-30Interim Results2024-12-30_8635821_interim-results.md0.58
  10. 2024-10-04Result OF Agm2024-10-04_8464176_result-of-agm.md0.20
  11. 2024-09-05Notice OF Agm2024-09-05_8402182_notice-of-agm.md0.14
  12. 2024-07-31Final Results2024-07-31_8339697_final-results.md0.45
  13. 2024-02-22Result OF Agm2024-02-22_8051787_result-of-agm.md0.14
  14. 2024-01-29Notice OF Agm2024-01-29_8011411_notice-of-agm.md0.14
  15. 2023-09-27Interim Results2023-09-27_7779920_interim-results.md0.23
  16. 2023-07-14Lifting OF Suspension2023-07-14_7633906_lifting-of-suspension.md0.25
  17. 2023-07-11Final Results2023-07-11_7626262_final-results.md0.25
  18. 2023-06-30Temporary Suspension Update2023-06-30_7604362_temporary-suspension-update.md0.25
  19. 2022-09-30Half Year Report2022-09-30_7171760_half-year-report.md0.23
  20. 2022-08-04Change OF Name2022-08-04_7009894_change-of-name.md0.15
  21. 2022-07-28Result OF Agm Amp Change OF Name2022-07-28_6916282_result-of-agm-amp-change-of-name.md0.15
  22. 2022-07-06Notice OF Agm2022-07-06_6873724_notice-of-agm.md0.07
  23. 2022-06-30Final Results2022-06-30_7119780_final-results.md0.25
  24. 2022-02-17Narf Acquisition And Approved Prospectus2022-02-17_6852298_narf-acquisition-and-approved-prospectus.md0.19
  25. 2021-10-29Half Year Report2021-10-29_6622411_half-year-report.md0.23

This research note was authored by a large language model after reading 22 regulatory filings published between 2021-10-29 and 2026-09-25. Each citation refers to a specific RNS announcement in the underlying data set. The note is an opinion, not advice. Do your own work before risking capital.